Failure to control AIDS-related CMV-retinitis with intravenous ganciclovir

Int Ophthalmol. 1992 Nov;16(6):453-7. doi: 10.1007/BF00918436.

Abstract

Between January 1988 and May 1991 intravenous ganciclovir (GCV) treatment was administered to eight male AIDS-patients with unilateral cytomegalovirus (CMV)-retinitis. Despite of continuous therapy with at least the recommended dose of GCV, three patients developed slowly progressive CMV-retinitis in the fellow eye after 4 to 13 months. The progression could not be stopped by GCV and thus bilateral blindness resulted after 12 to 22 months. The number of CD4-lymphocytes in the blood was reduced in all patients, but particularly in patients with progressive disease. Treatment failure was partly related to the duration of CMV-retinitis and partly to the degree of immunodeficiency. Intravenous treatment with GCV alone can not stop the progression of CMV-retinitis in long-term survivors and in those with advanced immunodeficiency.

MeSH terms

  • AIDS-Related Opportunistic Infections*
  • Adult
  • CD4-Positive T-Lymphocytes / metabolism
  • Cytomegalovirus Infections / complications
  • Cytomegalovirus Infections / prevention & control*
  • Eye Infections, Viral / complications
  • Eye Infections, Viral / prevention & control*
  • Fundus Oculi
  • Ganciclovir / administration & dosage
  • Ganciclovir / therapeutic use*
  • Humans
  • Infusions, Intravenous
  • Leukocyte Count
  • Male
  • Middle Aged
  • Retinitis / complications
  • Retinitis / microbiology
  • Retinitis / prevention & control*
  • Treatment Failure

Substances

  • Ganciclovir